SSB to equip Abzena's US-based development and manufacturing sites

4 Jan 2018

SSB will provide both facilities with end-to-end process solutions in single-use format.

Abzena has selected Sartorius Stedim Biotech (SSB) as its preferred equipment supplier in the US. SSB will equip Abzena's integrated CDMO facilities in Bristol, PA (development and GMP manufacture of antibody drug conjugates) and San Diego, CA (development and GMP manufacture of monoclonal antibodies and other recombinant proteins).

SSB to equip Abzena's US-based development and manufacturing sites

Sartorius Stedim will provide both facilities with end-to-end process solutions in single-use (SU) format. It will equip Abzena’s San Diego process development lab with leading industry technologies such as Ambr250, enabling fast scale up to 500 L initially and later to the 2000-L scale single-use bioreactor for its centre of excellence in clinical manufacturing.

John Burt, Abzena CEO, commented: “In addition to having selected Sartorius’ industry-leading single-use technologies for antibody and ADC production, the Abzena facilities will feature Umetrics process analytics software throughout the process ensuring that all the data captured throughout our clients’ molecule development is transformed into process knowledge ensuring that we can rapidly develop a robust and reliable process that can be easily scaled up to ensure a smooth technology transfer.”

Reinhard Vogt, Sartorius Executive VP commented: “We are pleased to have been selected by Abzena, a prominent global CDMO with a comprehensive industry portfolio across a wide range of modalities to supply single-use solutions that enable process development, tech transfer and GMP manufacturing. We look forward to working together to best serve the US and international markets.”

Read More

Related news

SIRIO Pharma opens multimillion gummy production plant

SIRIO Pharma opens multimillion gummy production plant

18 Oct 2018

The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.

Read more 
Tjoapack and Veratrak launch EPOCH initiative

Tjoapack and Veratrak launch EPOCH initiative

17 Oct 2018

The virtual platform is designed to allow the healthcare industry to effectively research and explore new technologies that will help to shape the future of the pharmaceutical supply chain.

Read more 
Cambrex invests $3m to upgrade generic API manufacturing facilities at Milan site

Cambrex invests $3m to upgrade generic API manufacturing facilities at Milan site

16 Oct 2018

The investment increases the overall capacity and capabilities of the facility, and its flexibility.

Read more 
Particle Sciences to open new commercial facility

Particle Sciences to open new commercial facility

15 Oct 2018

New facility will offer customers the full range of services from development through to commercial-scale manufacturing

Read more 
Generics companies to move away from little white pills

Generics companies to move away from "little white pills"

14 Oct 2018

Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.

Read more 
Pharma manufacturers warned to invest in continuous manufacturing

Pharma manufacturers warned to invest in continuous manufacturing

11 Oct 2018

CMOs hit by reduced volumes of opioid manufacturing from DEA quota changes, but cannabis sales to ignite.

Read more 
New portable and ready-to-use upper respiratory drug delivery solution

New portable and ready-to-use upper respiratory drug delivery solution

11 Oct 2018

PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.

Read more 
CPhI Worldwide announces the winners  of the 15th Pharma Awards

CPhI Worldwide announces the winners of the 15th Pharma Awards

10 Oct 2018

17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.

Read more 
CMOs to benefit from double digit approvals for ADCs in the next 3 years

CMOs to benefit from double digit approvals for ADCs in the next 3 years

9 Oct 2018

Therapeutic ADC market expected to reach $4 billion by 2023.

Read more 
Micro-Sphere increases capsule filling capacity

Micro-Sphere increases capsule filling capacity

8 Oct 2018

The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.

Read more